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In December 2019, a novel corona-virus designated SARS-CoV-2was identified in Wuhan (China). This one 
has caused an international outbreak 
of respiratory illness termed COVID-19. 
Initially, most infected people reported 
exposure to a large seafood and wet 
animal market in Wuhan, indicating a 
possible animal-to-human transmis-
sion; current data has demonstrated 
that person-to-person transmission is 
the most important way of spread. On 
30 January 2020, the WHO declared 
the COVID19 outbreak as a public heal-
th emergency of international concern 1. 
At the time of preparing this manuscript 
the WHO reported 372 757 confirmed 
cases and 16 231 deaths in more than 
180 countries. Currently, no therapeu-
tics have yet been proven effective for 
the treatment of severe illness caused 
by SARS-CoV-2. Several pre-existing 
and potencial drugs candidates inclu-
ding chloroquine, remdesivir, lopinavir 
and ritonavir have been considered1. 
The hydroxychloroquine (HCQ) and 
chloroquine have shown to have an in 
vitro activity against SARS-CoV-2 and 
a great number of virus and intrace-
llular micro-organisms. The HCQ and 
chloroquine had multiple activities that 
may explain the anti-viral effects, one of 
which is to alkalize the phagolysosome, 
which hampers the low-pH dependent 
step of viral replication including fu-
sion and uncoating, as well as interfe-
ring with the glycosylation of cellular 
receptors of SARS-CoV. However, the 
in vitro activity of these drugs has not 
translated into clinical effective activity 
for any viral infection. Based on recent 
report from China, the administration of 
chloroquine showed superiority com-
pared with the control group in terms of 
reduction of exacerbation of pneumo-
nia, duration of symptoms and delay 
of viral clearance. These results were 
obtained in absence of side effects 2. 
These results have led to include the 
chloroquine in the recommendation for 
management of COVID-19 pneumo-
nia. Regarding the treatment with HCQ 
both prescribing clinicians and patients 
should be aware that drug efficacy for 
COVID-19 is unclear because there is 
not sufficient evidence from randomi-
zed clinical trials. In the context of CO-
VID-19 treatment, the HCQ will be more 
effective if initiated as soon as possible. 
The principal candidates are patients 
with high-risk of poor outcomes. For 
optimal treatment, it may be necessary 
to administer a loading dosage (400 mg 
by mouth ever 12 hour) followed by a 
maintenance dosage (400 mg by mou-
th every day). Patients with gastrointes-
tinal intolerance may receive a dosage 
reduction. The optimal therapy duration 
is unclear, but should be prescribed for 
5 days. The treatment with HCQ is not 
recommended for patients with mul-
tiorgan failure, prolonged QT interval at 
baseline, documented cardiomyopathy 
or myocarditis. There is no experience 
to support the use of HCQ for pre-expo-
sure or post-exposure prophylaxis in in-
dividuals with confirmed or suspected 
exposure to SARS-CoV-2. 
Remdesivir is an adenosine analo-
gue that has demonstrated an in vitro 
anti-viral activity against SARS-CoV-2. 
This drug has not been approved an-
ywhere. Remdesivir has been recog-
nized as a promising antiviral drug 
against a wide array of RNA (including 
SARS-CoV and MERS-CoV), based on 
the evidence that the SARS-CoV and 
the SARS-CoV-2 share 82% RNA iden-
tity and their RNA-dependent RNA 
polymerase (RdRp) share 96% sequen-
ce identity, those drugs targeting viral 
RdRp proteins of SARS-CoV (like rem-
desivir) are likely to be affective against 
SARS-CoV-2 3. Recently, a report about 
the first case of COVID19 in Washin-
gton, USA, was published. This case 
was treated with remdesivir for the pro-
gression of pneumonia and the patient 
condition improved without side effects 
4. Although this preliminaries data on 
the anti-viral activity of remdesivir are 
promising, the translation of these 
into clinical practice is needed. There 
are two phase 3, randomized (Clinical-
Trials.gov Identifier: NCT04252664 and 
NCT04257656), doubled-blind, place-
bo-controlled multicenter clinical trials 
currently ongoing in China. These trials 
are designed to evaluate the efficacy 
and safety of remdesivir in hospitalized 
adults with mild-to-moderate and seve-
re COVID-19 pneumonia. These clinical 
trials may open the window to an effec-
tive anti-viral therapy.  
Lopinavir is a human immunodefi-
ciency virus (HIV) type 1 aspartate pro-
tease inhibitor, it has demonstrated in vi-
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Oral oseltamivir has been widely 
used for COVID-19 or suspected ca-
ses in China hospital. Oseltamivir is a 
neuraminidase inhibitor that has been 
used as antiviral treatment in influen-
za. The neuraminidase inhibitors are 
effective as empirical treatments in 
MERS-CoV infection, however, there is 
no exact evidence that oseltamivir is 
effective in the treatment of COVID-19 
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cyclosporine A, ebselen and cinanserin. 
The efficacy and safety of these drugs 
in the treatment of COVID-19 need to 
be confirmed in further preclinical and 
clinical trials.  
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